FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) ...

2025.08. 13 本文字数：957，阅读时长大约2分钟 作者 | 一财资讯 8月13日，沪指突破3674.4点，日线八连阳，创近4年新高。截至收盘，沪指涨0.48%，深成指涨 1.76%，创业板指涨3.62%。 | 代码 | 现价 涨跌 涨跌幅 | | --- | --- | | 000001 上证指数 | 3683.46c 17.55 0.48% | | 399001 深证成指 >> | 11551.36c 199.73 1.76% | | 899050 北证50 | 1461.86c 12.23 0.84% | | 881001 万得全A | 5801.59c 58.53 1.02% | | 000688 科别20 | 1077.70c 7.89 0.74% | | 399006 创业板指 | 2496.50c 87.11 3.62% | | 000300 沪深300 | 4176.58c 32.75 0.79% | 沪深两市全天成交额2.15万亿元，较昨日大幅放量。 个股涨多跌少，全市场超2700只个股上涨。 盘面上看，液冷服务器、工业金属、PEEK材料、CPO、光刻机等板块涨幅居前，煤炭、银行、 ...

Group 1: Market Performance - The three major indices showed strong performance, with the Shanghai Composite Index rising by 0.48%, surpassing last year's October high, while the Shenzhen Component Index increased by 1.76% and the ChiNext Index surged by 3.62% [1] - Over 2,600 stocks in the two markets experienced gains, with a total trading volume of approximately 2.15 trillion yuan [1] Group 2: Sector Highlights - The computing power, liquid cooling servers, and CPO concept stocks performed exceptionally well, with New Yisheng (300502.SZ) rising over 15%, and other notable gains from Zhongji Xuchuang (300308.SZ) at 11.66% and Cambridge Technology (603083.SH) at 9.93% [1] - PEEK materials saw collective strength, with companies like Huami New Materials (836247.BJ) and Xinhang New Materials (301076.SZ) experiencing significant increases [2] - The non-ferrous metals sector also performed well, with Electric Alloy (300697.SZ) rising over 9% and other companies like Luoyang Molybdenum (603993.SH) and Zhongfu Industrial (600595.SH) showing strong gains [2] Group 3: Economic Insights - Citic Securities noted that poor economic and employment data in the U.S. strengthened market expectations for a Federal Reserve rate cut in September, contributing to a broad rise in the non-ferrous metals sector [3] - The domestic push for "anti-involution" to optimize production factors is expected to enhance profitability across various sectors, benefiting metal prices [3] - The valuation of industrial metals is currently low, indicating potential for upward correction, with a bullish market for non-ferrous metals starting to emerge [3] Group 4: Policy and Market Sentiment - Dongguan Securities highlighted active market sentiment, suggesting an overweight position in the financial sector due to supportive policies aimed at enhancing the attractiveness of domestic capital markets [4] - The number of new A-share accounts opened in July reached 1.96 million, a significant year-on-year increase of 71%, indicating rising market participation and potential business opportunities for the securities industry [4] - Some sectors, including banks, coal, and logistics, experienced declines, with notable drops in stocks like Lu'an Huaneng (601699.SH) and Jiangsu Bank (600919.SH) [4]

Group 1 - CRO concept stocks have shown significant gains, with notable increases in share prices for companies such as Viatris (up 12.83% to HKD 2.11), Zhaoyan New Drug (up 9.23% to HKD 24.62), and others [1] - WuXi AppTec has raised its full-year sales forecast after reporting a 141.6% year-on-year increase in TIDES business revenue, reaching RMB 5.03 billion in the first half of the year, driven by high demand in the GLP-1 sector [1] - CICC believes that the valuation center for innovative drug sectors has been adjusted upwards, which will enhance domestic new drug R&D demand and increase financing activity for primary innovative drug projects [1] Group 2 - The U.S. Bureau of Labor Statistics reported stable inflation in July, reducing barriers for potential interest rate cuts by the Federal Reserve in September, indicating a recovery trend in overall investment and financing [2] - The domestic market for preclinical CRO, clinical CRO, and CDMO services has stabilized in pricing, with a steady recovery in new orders expected to lead to an industry turnaround [2] - Internationally, the CDMO pricing system remains reasonable, and the impact of high pandemic baselines has been absorbed, suggesting a positive trend for overseas orders [2]

市场全天震荡走高，沪指突破去年10月8日高点，创近4年新高。截至收盘，沪指涨0.48%，深成指涨1.76%，创业板指涨3.62%。 盘面上，市场热点较为杂乱，个股涨多跌少，全市场超2700只个股上涨。 从板块来看，AI硬件股持续爆发，工业富联等多股续创历史新高。 券商股一度冲高，国盛金控2连板。 有色金属概念股震荡走强，紫金矿业、洛阳钼业双双创历史新高。 沪深两市成交额合计2.15万亿元，较上一交易日放量约2694.17亿元。其中，沪市成交额8870.23亿元，深市成交额1.26万亿元。 个股方面，东方财富成交额居首，为204亿元。其后是新易盛、中际旭创、寒武纪-U、宁德时代，成交额分别为135亿元、133亿元、114亿元、 107亿元。 | 序号 代码 名称 | | | | | | 【 ◎ 【 】 【 】 【 】 】 【 】 【 】 【 】 【 】 【 】 】 】 】 】 【 】 【 】 【 】 【 】 【 】 【 】 【 】 【 】 【 】 】 】 【 】 】 】 【 】 】 】 】 【 】 】 】 】 【 】 】 】 【 】 】 】 【 】 】 】 【 】 【 】 】 】 【 】 【 】 】 】 【 】 ...

Core Viewpoint - The innovative drug concept stocks have shown strong performance recently, driven by favorable policy developments and market dynamics [1][4][5]. Group 1: Market Performance - Innovative drug stocks surged, with Shouyao Holdings hitting a 20% limit up and Haishike also reaching the limit, alongside significant gains from companies like WuXi AppTec and MediSino [1][5]. - Since the start of the current market rally on April 8, the innovative drug sector has seen an overall increase of nearly 60%, with individual stocks like Shutai Shen rising nearly 7 times and Guangsheng Tang over 4 times [5][6]. Group 2: Policy Developments - The National Medical Insurance Administration (NMI) announced that 534 drugs passed the preliminary review for the 2025 National Medical Insurance Drug List, a significant increase from 2024 [4][6]. - A new commercial insurance innovative drug list was established, with 121 drugs approved, indicating a shift towards integrating commercial health insurance with basic medical insurance [6][7]. - The NMI's recent meetings emphasized support for genuine innovation in the pharmaceutical sector, aiming to enhance the quality of drugs and medical devices while rejecting subpar innovations [7][8]. Group 3: Industry Outlook - Analysts are optimistic about the investment opportunities within the pharmaceutical industry, driven by supportive policies and the potential for market recovery in the second half of 2025 [8][9]. - The total market size for innovative drugs in China is estimated to be between 200 billion and 300 billion, with significant growth potential as the country becomes a global R&D hub for innovative drugs [9]. - The policy environment remains favorable for innovative drugs, with major pharmaceutical companies gradually clearing risks associated with drug procurement, paving the way for competitive innovative drug pipelines [9].

Group 1 - The A-share market is experiencing a surge in the pharmaceutical sector, particularly in innovative drugs, with Hai Si Ke reaching its daily limit and Di Zhe Pharmaceutical rising over 8% [1] - The National Healthcare Security Administration has announced the preliminary review of 121 drug names for inclusion in the commercial insurance innovative drug directory, including high-priced CAR-T cancer drugs [1] - The medical sector is seeing a rebound driven by CXO, with the largest medical ETF (512170) hitting a 1.9% increase, and major stocks like Zhaoyan New Drug rising over 8% [3] Group 2 - A new action plan for the high-quality development of "Artificial Intelligence + Healthcare" in Zhejiang Province has been released, focusing on creating multimodal medical industry models and specialized healthcare models [5] - Recent institutional insights suggest that the pharmaceutical sector, led by innovative drugs, is viewed positively for long-term investment, while medical devices are also gaining attention [5] - The largest medical ETF (512170) focuses on medical devices (52%) and medical services (40%), with a strong correlation to AI healthcare, covering six leading CXO stocks [6]

Group 1 - The Hong Kong stock market showed strong performance on August 13, with the Hang Seng Index rising by 1.88% and the Hang Seng Tech Index increasing by 2.35%, particularly driven by the healthcare sector [1] - The Hong Kong Innovative Drug 50 ETF (513780) closed up by 3.38% with a turnover rate exceeding 18% and a transaction volume of over 400 million yuan, indicating strong investor interest [1] - Notably, the Hong Kong Innovative Drug 50 ETF (513780) experienced a net inflow of 1.07 billion yuan over the past 15 trading days, and it has gained over 92% year-to-date as of August 12 [1] Group 2 - The National Healthcare Security Administration announced the preliminary review results for the 2025 medical insurance directory and commercial insurance innovative drug directory, with 534 drugs passing the basic medical insurance directory review and 121 drugs passing the commercial insurance innovative drug directory review [2] - High-priced innovative drugs, including CAR-T therapies, are seeking inclusion in the commercial insurance innovative drug directory, indicating a push for diversified payment methods for innovative drugs [2] - Analysts suggest that the rise of innovative drugs is sustainable, recommending attention to companies with rich pipeline layouts, high-potential single innovative drugs, and leading technology platforms in the sector [2]

Core Viewpoint - WuXi AppTec (603259) is expected to achieve approximately 20.64% year-on-year revenue growth, reaching about 20.799 billion yuan in the first half of 2025, with a net profit attributable to shareholders expected to increase by approximately 101.92% to about 8.561 billion yuan [1] Group 1: Company Performance - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, expanding new capabilities and production capacity while optimizing production processes and improving operational efficiency [1] - As of the end of 2024, WuXi AppTec has approximately 6,000 active clients, with about 5,500 in its ongoing business, and added around 1,000 new clients throughout the year [2] - The company's backlog for ongoing business reached 49.31 billion yuan, representing a year-on-year increase of 47.0% [2] Group 2: Industry Context - The performance of WuXi AppTec is closely linked to the development of the global pharmaceutical industry and investments in new drug research and development [1] - The global pharmaceutical market is expected to continue growing due to factors such as economic development, population growth, aging demographics, technological advancements, rising healthcare expenditures, and increasing public demand for healthy living [1]

Core Insights - WuXi AppTec (603259) reported a strong performance in the first half of 2025, with revenue reaching 20.799 billion yuan, a year-on-year increase of 20.64%, and net profit attributable to shareholders rising by 101.92% to 8.56 billion yuan [1][2] Group 1: Financial Performance - The company achieved a revenue of 20.41 billion yuan from continuing operations, with a year-on-year growth of 24.24% [1] - The TIDES business (oligonucleotides and peptides) saw significant growth, with revenue reaching 5.03 billion yuan, a year-on-year increase of 141.6% [2] - The company completed cash dividends totaling 3.84 billion yuan in the first half of 2025, including 2.83 billion yuan for the 2024 fiscal year and a special dividend of 1.01 billion yuan for 2025 [2] Group 2: Business Operations and Growth - The company reported a backlog of orders for continuing operations amounting to 56.69 billion yuan, a year-on-year increase of 37.2% [1] - Revenue from U.S. clients was 14.03 billion yuan, reflecting a year-on-year growth of 38.4%, while European clients contributed 2.33 billion yuan, growing by 9.2% [1] - The company is expanding its global footprint, with successful FDA inspections at its Changzhou and Taixing API bases and ongoing construction of its Middleton facility in the U.S. expected to be operational by the end of 2026 [3] Group 3: Future Outlook - The company raised its full-year revenue guidance, expecting a growth rate for continuing operations to be adjusted from 10%-15% to 13%-17% [3] - Overall revenue guidance was increased from 41.5 billion yuan - 43 billion yuan to 42.5 billion yuan - 43.5 billion yuan [3] - The CEO highlighted the unique advantages of the CRDMO business model and the commitment of the global team as key factors driving the company's strong growth momentum [3]